

**Aragen Life Sciences B.V.**  
**Utrecht, the Netherlands**

**Financial Statements 2023/2024**

**Aragen Life Sciences B.V.**  
**Utrecht, the Netherlands**

**Financial Statements 2023/2024**

<b>TABLE OF CONTENTS</b>		<b>Page</b>
<b>1.</b>	<b>Financial report</b>	
1.1	Balance sheet as of March 31, 2024	2
1.2	Profit and loss account 2023/2024	4
1.3	Notes to the financial statements	5
1.4	Notes to the balance sheet	8
1.5	Notes to the profit and loss account	12
<b>2.</b>	<b>Other information</b>	
2.1	Legal exemption	15
2.2	Statutory rules concerning appropriation of result	15
2.3	Appropriation of result for the financial year 2022/2023	15

**1.1 Balance sheet as of March 31, 2024**

(After result appropriation)

	March 31, 2024		March 31, 2023	
<b>ASSETS</b>	€	€	€	€
<b>Fixed assets</b>				
<i>Tangible fixed assets</i>				
Computers	3.031		-	
		3.031		-
<b>Current assets</b>				
<i>Receivables</i>				
Trade debtors	125.146		119.060	
Taxes	10.899		17.678	
Other receivables	-		147.126	
		136.045		283.864
<i>Cash and cash equivalents</i>		244.594		390.889
<b>Total assets</b>		383.670		674.753

**1.1 Balance sheet as of March 31, 2024**

(After result appropriation)

<b>EQUITY AND LIABILITIES</b>	<u>March 31, 2024</u>		<u>March 31, 2023</u>	
	€	€	€	€
<b>Shareholders' equity</b>				
Issued share capital	391.141		391.141	
Other reserves	<u>-148.638</u>		<u>-269.391</u>	
		242.503		121.750
<b>Current liabilities</b>				
Creditors	76.533		45.607	
Debts to shareholders and related parties	-		459.770	
Taxes	25.957		17.300	
Accrued liabilities	<u>38.677</u>		<u>30.326</u>	
		141.167		553.003
<b>Total shareholder's equity and liabilities</b>		<u><u>383.670</u></u>		<u><u>674.753</u></u>

**1.2 Profit and loss account 2023/2024**

	2023/2024		2022/2023	
	€	€	€	€
Net turnover		1.545.083		1.667.141
Cost of sales		265.652		396.383
<b>Gross operating result</b>		<u>1.279.431</u>		<u>1.270.758</u>
Wages and salaries	721.462		634.870	
Social security charges	86.374		111.337	
Depreciation tangible fixed assets	320		-	
Other personnel expenses	184.987		194.657	
Selling expenses	7.821		34.278	
Travel and car expenses	129.211		134.299	
Office expenses	8.004		8.623	
General expenses	43.154		61.638	
<b>Total operating costs</b>		<u>1.181.333</u>		<u>1.179.702</u>
<b>Operating result</b>		<u>98.098</u>		<u>91.056</u>
Interest income and similar revenues	1.076		-	
Interest expenses and similar charges	-3.045		-15.059	
<b>Total financial income and expenses</b>		<u>-1.969</u>		<u>-15.059</u>
Result before taxation		<u>96.129</u>		<u>75.997</u>
Taxation		-3		-
<b>Result after taxation</b>		<u><u>96.126</u></u>		<u><u>75.997</u></u>

## **1.3 Notes to the financial statements**

### **GENERAL**

#### **Company**

Aragen Life Sciences B.V. (the Company) is a private company with limited liability incorporated under the laws of the Netherlands on 28 June 2013, having its statutory seat in Breda, the Netherlands and its registered address at Utrechtseweg 22B in Utrecht.

The Company is registered at the Dutch Chamber of Commerce under number 58267026.

#### **Activities**

The activities of the Company are:

- Biotechnical research and development on medical products and pharmaceutical processes and of food;
- Biotechnical research and development on agricultural products and processes;
- Financing and holdings;
- Marketing and sales support to group companies.

#### **Group structure**

The Company's sole shareholder is Aragen Life Sciences Limited located in India.

#### **Related-party transactions**

All legal entities that can be controlled, jointly controlled or significantly influenced are considered to be a related party.

Also, entities which can control the Company are considered a related party. In addition, statutory directors, other key management of Aragen Life Sciences B.V. [or the ultimate parent company] and close relatives are regarded as related parties.

Significant transactions with related parties are disclosed in the notes insofar as they are not transacted under normal market conditions. The nature, extent and other information is disclosed if this is required for to provide the true and fair view.

#### **Estimates**

The preparation of financial statements in conformity with the relevant rules requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group's accounting policies. If necessary for the purposes of providing the view required under Section 362(1), Book 2, of the Dutch Civil Code, the nature of these estimates and judgments, including the related assumptions, is disclosed in the notes to the financial statement items in question.

#### **Translation of foreign currencies**

Receivables, liabilities and obligations denominated in foreign currency are translated at the exchange rates prevailing at balance sheet date.

Transactions in foreign currency during the financial year are recognised in the financial statements at the exchange rates prevailing at transaction date. The exchange differences resulting from the translation as of balance sheet date, taking into account possible hedge transactions, are recorded in the profit and loss account.

#### **Proposed appropriation of result for the financial year 2023/2024**

The board of directors proposes to the general meeting that the result for the 2023/2024 financial year, amounting to € 96.126 should be transferred fully to other reserves and that no dividend should be paid.

This proposal has been already incorporated in the financial statements.

#### **Subsequent events**

No events have occurred since balance sheet date, which would change the financial position of the Company and which would require adjustments of or disclosure in the annual accounts now presented.

### **1.3 Notes to the financial statements**

#### **PRINCIPLES OF VALUATION OF ASSETS AND LIABILITIES**

##### **General**

The financial statements have been prepared in accordance with Title 9, Book 2, of the Dutch Civil Code. The statements are prepared in euro. Assets and liabilities are valued at nominal value unless stated otherwise.

The financial statements have been valued at fiscal values as provided for by article 396 section 6, Book 2 of the Dutch Civil code.

Valuation of assets and liabilities and determination of the result takes place under the historical cost convention. Unless presented otherwise, the relevant principle for the specific balance sheet item, assets and liabilities are presented at face value.

Income and expenses are accounted for on accrual basis. Profit is only included when realized on balance sheet date. Losses originating before the end of the financial year are taken into account if they have become known before preparation of the financial statements.

##### **Tangible fixed assets**

The tangible fixed assets are valued at acquisition price or manufacturing costs, less the accumulated depreciation and any impairments. The depreciation is based on the expected useful life and is calculated on the basis of a fixed percentage of the acquisition price or manufacturing costs, taking into account any residual value. Depreciation is applied as from the moment the asset is put to use.

Depreciation percentages:

Computers	20 %
-----------	------

##### **Receivables**

Trade receivables are recognised initially at fair value and subsequently measured at amortised cost. If payment of the receivable is postponed under an extended payment deadline, fair value is measured on the basis of the discounted value of the expected revenues. Interest gains are recognised using the effective interest method. When a trade receivable is uncollectible, it is written off against the allowance account for trade receivables.

##### **Cash and cash equivalents**

Cash and cash equivalents are valued at nominal value and, insofar as not stated otherwise, is at the free disposal of the company.

##### **Current liabilities**

The current liabilities concern the liabilities with a duration shorter than one year. Borrowings are initially recognized at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortised cost, being the amount received taking account of any premium or discount, less transaction costs.

### **1.3 Notes to the financial statements**

#### **PRINCIPLES FOR THE DETERMINATION OF THE RESULT**

##### **General**

Revenues from services are recognised in proportion to the services rendered based on the cost-incurred in respect of the service performed up to balance sheet date in proportion to the estimated costs of the aggregate services to be performed. The cost price of these services is allocated to the same period.

##### **Net turnover**

Net turnover represents the total amount received by the Company for the sale of goods and services rendered to third parties.

Revenues from services are recognised in proportion to the services rendered. The cost price of these services is allocated to the same period.

##### **Cost of sales**

The purchase value of the turnover consists of the costs of delivered goods and services, which are directly attributable to this deliveries. This value includes the movement in devaluation because of unmarketable stocks.

##### **Operating costs**

Costs are attributed to the financial year to which they relate. Profits are accounted for in the year in which goods have been provided or services have been performed. Losses are assumed in the year in which these are foreseeable.

##### **Employee benefits**

Wages, salaries and social security contributions are recognized in the profit and loss account on the basis of the conditions of employment to the extent that they are owed to employees.

##### **Amortisation and depreciation**

Intangible assets, including goodwill, are amortised and property, plant and equipment depreciated over their estimated useful lives as from the inception of their use. Land and investment property are not depreciated. Future depreciation and amortisation is adjusted if there is a change in estimated future useful life.

##### **Financial income and expenses**

Interest paid and received is recognised on a time-weighted basis, taking account of the effective interest rate of the assets and liabilities concerned. When recognising interest paid, allowance is made for transaction costs on loans received as part of the calculation of effective interest.

##### *Exchange differences*

Exchange differences arising upon the settlement or conversion of monetary items are recognised in the profit and loss account in the period that they arise, unless they are hedged.

##### **Taxation**

Corporate income tax is calculated at the applicable rate on the result for the financial year, taking into account permanent differences between profit calculated according to the financial statements and profit calculated for taxation purposes, and with which deferred tax assets (if applicable) are solely measured insofar as their realisation is likely.



## 1.4 Notes to the balance sheet

### ASSETS

#### FIXED ASSETS

##### Tangible fixed assets

A summary of the movements of tangible fixed assets is given below:

	Computers €
Acquisition value	-
Accumulated depreciations	-
Book value as of April 1, 2023	-
Investments	3.351
Depreciations	-320
Movements 2023/2024	3.031
Acquisition value	3.351
Accumulated depreciations	-320
Book value as of March 31, 2024	3.031

#### CURRENT ASSETS

##### Receivables

	March 31, 2024 €	March 31, 2023 €
<b>Trade debtors</b>		
Balance as of	125.146	119.060

A provision for doubtful debtors is not considered to be necessary.

	March 31, 2024 €	March 31, 2023 €
<b>Taxes</b>		
Corporate income tax	10.899	17.163
Value added tax	-	515
	10.899	17.678

	March 31, 2024 €	March 31, 2023 €
<b>Other receivables</b>		
Amounts paid but not received by counterparty	-	147.126

**1.4 Notes to the balance sheet**

	March 31, 2024	March 31, 2023
	€	€
<b>Cash and cash equivalents</b>		
Citibank EUR account	206.604	386.980
Citibank USD account	37.968	3.888
Citibank GBP account	22	21
	<u>244.594</u>	<u>390.889</u>

Cash and cash equivalents are at free disposal of the Company.

**1.4 Notes to the balance sheet**

**SHAREHOLDERS' EQUITY AND LIABILITIES**

**SHAREHOLDERS' EQUITY**

	<u>2023/2024</u>	<u>2022/2023</u>
	€	€
<b>Issued share capital</b>		
Balance as of 31 March	<u>391.141</u>	<u>391.141</u>

The initial issued share capital amounts to € 1, divided into 1 ordinary share with a nominal value of € 1 per share. In December 2014 another 391,140 ordinary shares have been issued with a nominal value of € 1 par share. On the balance sheet date all shares have been paid in.

	<u>2023/2024</u>	<u>2022/2023</u>
	€	€
<b>Other reserves</b>		
Balance as of 1 April	-269.391	-352.431
From proposal profit appropriation	96.126	75.997
Contribution from Aragen India regarding ESOP	24.627	7.043
Balance as of 31 March	<u>-148.638</u>	<u>-269.391</u>

Aragen Life Sciences Limited provides in an Employee Stock Option Plan (ESOP) for eligible employees of the Aragen group. As a result Aragen Life Sciences Limited has granted share options to the employees of the Company. The options are granted with a vesting period of 1 year.

**1.4 Notes to the balance sheet**

**CURRENT LIABILITIES**

	March 31, 2024	March 31, 2023
	€	€
<b>Creditors</b>		
Balance as of	76.533	45.607
	March 31, 2024	March 31, 2023
	€	€
<b>Debts to shareholders and related parties</b>		
Loan from Aragen Life Sciences Limited	-	459.770
	2023/2024	2022/2023
	€	€
<i>Loan from Aragen Life Sciences Limited</i>		
Balance as of 1 April	459.770	450.410
Payment / (repayment)	-466.163	-
Currency exchange difference	6.393	9.360
Balance as of 31 March	-	459.770

Above loan was initially made and executed on 1 October 2014 for a period of one year and renewed till 30 September 2017. The interest is at 3 months USD Libor rate plus 500 BPS per annum on the month end outstanding balance. Libor rate is fixed at the beginning of respective quarter. No securities have been determined.

The loan has been used to fund the subsidiary GBO LLC. Since the subsidiary has been dissolved and the Company did not receive any gain out of the dissolution, the lender and the Company agreed to stop charging interest as of January 2017.

	March 31, 2024	March 31, 2023
	€	€
<b>Taxes</b>		
Value added tax	8.471	-
Wage tax	17.486	17.300
	25.957	17.300
	March 31, 2024	March 31, 2023
	€	€
<b>Accrued liabilities</b>		
Accrued personnel expenses	17.087	1.555
Accrued wages (GB part)	21.390	17.940
Accrued administration charges	200	10.831
	38.677	30.326

**1.5 Notes to the profit and loss account**

	<u>2023/2024</u>	<u>2022/2023</u>
	€	€
<b>Net turnover</b>		
Turnover outside EU	1.364.110	1.396.936
Turnover inside EU	124.243	195.634
Turnover inside the Netherlands	56.730	74.571
	<u>1.545.083</u>	<u>1.667.141</u>
<b>Cost of sales</b>		
Purchases outside EU	<u>265.652</u>	<u>396.383</u>
<b>Wages and salaries</b>		
Wages and salaries (NL part)	608.185	460.747
Wages and salaries (IT part)	109.827	173.166
Holiday payments	3.450	957
	<u>721.462</u>	<u>634.870</u>
Average number of employees:		
During the year 2023/2024 an average of 4 employees has been in service on base of a fulltime employment. The year 2022/2023 counted 3 employees.		
<b>Social security charges</b>		
Social security charges (IT part)	36.858	66.143
Social security charges (NL part)	49.516	45.194
	<u>86.374</u>	<u>111.337</u>
<b>Depreciation tangible fixed assets</b>		
Prepaid on tangible fixed assets	<u>320</u>	<u>-</u>
<b>Other personnel expenses</b>		
Expense allowance	133.488	112.161
Education and training expenses	14.035	59.907
Insurances	11.646	15.546
Other personnel expenses	1.192	-
Employee Stock Ownership Plan (ESOP) Aragen Life Sciences Limited	24.626	7.043
	<u>184.987</u>	<u>194.657</u>
<b>Selling expenses</b>		
Seminars and conferences expenses	<u>7.821</u>	<u>34.278</u>


**1.5 Notes to the profit and loss account**

	<u>2023/2024</u>	<u>2022/2023</u>
	€	€
<b>Travel and car expenses</b>		
Travel and hotel expenses	100.561	73.387
Food, drinks and beverages NL	11.923	7.702
Airfare and train expenses	4.618	24.771
Taxi and car expenses	3.602	10.108
Food, drinks and beverages IT	2.535	4.901
Fines	35	-
Other car expenses	341	-
Lease cars	5.596	13.430
	<u>129.211</u>	<u>134.299</u>
<b>Office expenses</b>		
Telecommunication	7.198	7.862
Postage costs	-	568
Stationery costs	806	193
	<u>8.004</u>	<u>8.623</u>
<b>General expenses</b>		
Administrative charges	13.761	13.556
Consultancy charges payroll	7.888	10.559
Legal charges	5.080	7.031
Tax advisory charges	5.880	6.360
Promotional expenses	2.830	974
Chamber of Commerce	-	25
Other general expenses	7.715	23.133
	<u>43.154</u>	<u>61.638</u>

**1.5 Notes to the profit and loss account**

	<u>2023/2024</u>	<u>2022/2023</u>
	€	€
<b>Financial income and expenses</b>		
<b>Interest income and similar revenues</b>		
Interest received	<u>1.076</u>	<u>-</u>
<b>Interest expenses and similar charges</b>		
Currency exchange rate differences	3.045	8.875
Banking fees and provision	-	6.184
	<u>3.045</u>	<u>15.059</u>
<b>Taxation</b>		
Corporate income tax previous years	<u>3</u>	<u>-</u>

Utrecht,  
Aragen Life Sciences B.V.

  
M. Kantipudi

  
S.R. Mamidi

## **2. Other information**

### **2.1 Legal exemption**

The Company has utilized the exemption from an audit by virtue of article 2:396 paragraph 7 of the Dutch Civil Code.

### **2.2 Statutory rules concerning appropriation of result**

The profit is at free disposal of the general meeting of shareholders, as stated in article 19.1 of the articles of association.

### **2.3 Appropriation of result for the financial year 2022/2023**

The financial statements 2022/2023 is adopted in the general meeting of shareholders held on 22 December 2023. The general meeting of shareholders has adopted the appropriation of result in accordance with the proposal being made to that end.